Medicus Pharma Ltd. MDCX
Medicus Pharma Ltd. (Nasdaq: MDCX) is an oncology drug developer. Its lead program, SkinJect (doxorubicin dissolvable microneedle array, D-MNA), is in Phase 2 for Basal cell carcinoma (nodular BCC) and Gorlin syndrome.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SkinJect D-MNA (SKNJCT-003 / SKNJCT-004) | Nodular basal cell carcinoma (Phase 2; SKNJCT-003 completed, SKNJCT-004 ongoing in UAE; 505(b)(2) path aligned with FDA) | device-combination | Phase 2 |
| SkinJect D-MNA (SKNJCT-005) | Gorlin syndrome with multiple BCCs (registrational Phase 2b, FDA 'Study May Proceed' July 2026) | device-combination | Phase 2 |
| Teverelix | Advanced prostate cancer, high CV risk (Phase 2b cleared by FDA) | protein/peptide | Phase 2 |
| Teverelix | Prevention of recurrent acute urinary retention (optimized Phase 2, FDA feedback July 2026) | protein/peptide | Phase 2 |
| Teverelix PRECISION-E2 | Endometriosis (Phase 2a, UAE IND authorized July 2026) | protein/peptide | Phase 2 |
Recent results and decisions
- Oct 23, 2026n/a Medicus Pharma regained compliance with Nasdaq's $1.00 minimum bid price requirement after maintaining closing bid price at or above $1.00 for ten consecutive business days from October 12-23, 2026.
Nasdaq had determined that for the last ten consecutive business days, from October 12, 2026 to October 23, 2026, the closing bid price of the Shares had been at $1.00 per Share or greater and that, accordingly, the Company had regained compliance with the Minimum Bid Price Requirement and that the
Filing - Nov 14, 2025started First patient treated in October 2025 in the SKNJCT-004 randomized study in the UAE (36 patients planned).
In October 2025, the Company treated its first patient in the clinical study (SKNJCT-004) currently underway in the United Arab Emirates (UAE).
Filing - Nov 14, 2025n/a UK MHRA, HRA and WREC granted approvals to expand Phase 2 SKNJCT-003 into the United Kingdom (ex-US regulatory action).
In November 2025, the company received full regulatory and ethical approvals in the United Kingdom to expand its ongoing Phase 2 clinical study (SKNJCT-003) evaluating D-MNA to non-invasively treat BCC of the skin.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.